CY1111932T1 - Συνδυασμοι αγωνιστικης βητα-2-αδρενεργικης βενζοθειαζολονης - Google Patents

Συνδυασμοι αγωνιστικης βητα-2-αδρενεργικης βενζοθειαζολονης

Info

Publication number
CY1111932T1
CY1111932T1 CY20111100976T CY111100976T CY1111932T1 CY 1111932 T1 CY1111932 T1 CY 1111932T1 CY 20111100976 T CY20111100976 T CY 20111100976T CY 111100976 T CY111100976 T CY 111100976T CY 1111932 T1 CY1111932 T1 CY 1111932T1
Authority
CY
Cyprus
Prior art keywords
inhibitor
receptor
hydroxy
ethyl
ylacetoxy
Prior art date
Application number
CY20111100976T
Other languages
English (en)
Inventor
Elaine Bridget Cadogan
Stephen Connolly
David John Nicholls
Katherine Elisabeth Wiley
Alan Young
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1111932T1 publication Critical patent/CY1111932T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση παρέχει ένα φαρμακευτικό προϊόν που περιλαμβάνει ένα πρώτο δραστικό συστατικό, το οποίο είναι Ν-[2-(Διαιθυ-λαμινο)αιθυλ]-Ν-(2-{[2-(4-υδροξυ-2-οξο-2,3-διυδρο-1,3-βενζοθειαζολ-7-υλ)αιθυλ]αμινο}αιθυλ)-3-[2-(1-ναφθυλ)αιθοξυ]προπαναμίδιο ή ένα άλας αυτού, και ένα δεύτερο δραστικό συστατικό που επιλέγεται από: ένα μη-στεροειδή Αγωνιστή Υποδοχέος Γλυκοκορτικοειδούς (Υποδοχέας GR)˙ ένα αντιοξειδωτικό˙ έναν ανταγωνιστή CCR1˙ έναν ανταγωνιστή χημοκίνης (όχι μη CCR1)˙ ένα κορτικοστεροειδές˙ έναν ανταγωνιστή CRTh2˙ έναν ανταγωνιστή DP1˙ έναν Επαγωγέα Αποακετυλάσης της Ιστόνης˙ έναν αναστολέα ΙΚΚ2˙ έναν αναστολέα COX˙ έναν αναστολέα λιποξυγενάσης˙ έναν ανταγωνιστή υποδοχέος λευκοτριενίου˙ έναν αναστολέα ΜΡΟ˙ έναν μουσκαρινικό ανταγωνιστή ο οποίος είναι βρωμιούχο Ακλιδίνιο, Γλυκοπυρρολάτη, βρωμιούχο Οξιτρόπιο, Πιρενζεπίνη, τελενζεπίνη, βρωμιούχο Τιοτρόπιο, 3(R)-(2-υδροξυ-2,2-διεθειεν-2-υλακετοξυ)-1-(3-φαινοξυπροπυλ)-1-αζο-νιαδικυκλο[2.2.2]οκτάνιο βρωμιούχο, 3(R)-1-φαιναιθυλ-3-(9Η-ξανθανο-9-καρβονυλοξυ)-1-αζονιαδικυκλο[2.2.2]οκτάνιο βρωμιούχο ή (3R)-3-[(2S)-2-κυκλοπεντυλ-2-υδροξυ-2-θειεν-2-υλακετοξυ]-1-(2-φαινοξυαιθυλ)-1-αζονιαδικυκλο[2.2.2] ακτάνιο βρωμιούχο˙ έναν αναστολέα p38˙ έναν αναστολέα PDE˙ έναν αγωνιστή PPARy˙ έναν αναστολέα πρωτεάσης˙ μία Στατίνη˙ έναν ανταγωνιστή θρομβοξάνης˙ έναν αγγειοδιασταλτικό παράγοντα˙ ή, έναν αναστολέα ENAC (αναστολέας διαύλου Νατρίου Επιθηλίων)˙ και τη χρήση του στη θεραπευτική αντιμετώπιση αναπνευστικών παθήσεων.
CY20111100976T 2007-02-08 2011-10-12 Συνδυασμοι αγωνιστικης βητα-2-αδρενεργικης βενζοθειαζολονης CY1111932T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0702456.5A GB0702456D0 (en) 2007-02-08 2007-02-08 New combination
EP08702047A EP2117542B1 (en) 2007-02-08 2008-02-06 Combinations of beta- 2 -adrenoceptor agonistic benzothiazolone

Publications (1)

Publication Number Publication Date
CY1111932T1 true CY1111932T1 (el) 2015-11-04

Family

ID=37898976

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100976T CY1111932T1 (el) 2007-02-08 2011-10-12 Συνδυασμοι αγωνιστικης βητα-2-αδρενεργικης βενζοθειαζολονης

Country Status (29)

Country Link
US (2) US20100029732A1 (el)
EP (2) EP2117542B1 (el)
JP (1) JP2010518056A (el)
KR (1) KR20090114391A (el)
CN (1) CN101652137A (el)
AR (1) AR065277A1 (el)
AT (1) ATE520401T1 (el)
AU (1) AU2008212713A1 (el)
BR (1) BRPI0806964A2 (el)
CA (1) CA2675465A1 (el)
CL (1) CL2008000379A1 (el)
CO (1) CO6210723A2 (el)
CY (1) CY1111932T1 (el)
DK (1) DK2117542T3 (el)
EC (1) ECSP099567A (el)
ES (1) ES2368967T3 (el)
GB (1) GB0702456D0 (el)
HR (1) HRP20110695T1 (el)
IL (1) IL199840A0 (el)
MX (1) MX2009007865A (el)
PE (1) PE20081759A1 (el)
PL (1) PL2117542T3 (el)
PT (1) PT2117542E (el)
RS (1) RS51956B (el)
RU (1) RU2009133255A (el)
SI (1) SI2117542T1 (el)
TW (1) TW200843750A (el)
UY (1) UY30906A1 (el)
WO (1) WO2008096111A1 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
NZ589091A (en) 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
CN102908624A (zh) * 2008-05-13 2013-02-06 阿斯利康(瑞典)有限公司 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
CN102124003A (zh) 2008-06-18 2011-07-13 阿斯利康(瑞典)有限公司 作为治疗呼吸系统疾病的β2肾上腺素受体拮抗剂的苯并噁嗪酮衍生物
UY31920A (es) * 2008-06-20 2010-01-29 Astrazeneca Ab Nueva combinacion-408
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
WO2010108013A1 (en) * 2009-03-18 2010-09-23 The Trustees Of The University Of Pennsylvania Compositions and methods for treating asthma and other lung diseases
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011011060A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
DK3191081T3 (da) 2014-09-09 2020-06-15 Vectura Ltd Formulering, som omfatter glycopyrrolat, fremgangsmåde og indretning
CA2983668C (en) * 2015-05-04 2023-06-27 Astrazeneca Ab Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors
IL281809B (en) 2018-09-28 2022-09-01 Karuna Therapeutics Inc Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE378109B (el) 1972-05-19 1975-08-18 Bofors Ab
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0104251D0 (sv) 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
GB0402797D0 (en) * 2004-02-09 2004-03-10 Novartis Ag Organic compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
CN101048407A (zh) 2004-09-03 2007-10-03 普莱希科公司 双环杂芳基pde4b抑制剂
EP1807391A4 (en) 2004-10-29 2010-01-06 Astrazeneca Ab NOVEL SULFONAMIDE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND FOR THE TREATMENT OF INFLAMMATORY DISEASES
JPWO2006098353A1 (ja) 2005-03-15 2008-08-28 協和醗酵工業株式会社 外用剤
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
CN101553493B (zh) 2006-07-19 2012-07-04 阿斯利康(瑞典)有限公司 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途

Also Published As

Publication number Publication date
ES2368967T3 (es) 2011-11-24
US20080242649A1 (en) 2008-10-02
RU2009133255A (ru) 2011-03-20
CO6210723A2 (es) 2010-10-20
PE20081759A1 (es) 2009-01-31
EP2117542A1 (en) 2009-11-18
ATE520401T1 (de) 2011-09-15
CN101652137A (zh) 2010-02-17
PL2117542T3 (pl) 2011-12-30
TW200843750A (en) 2008-11-16
HRP20110695T1 (hr) 2011-11-30
DK2117542T3 (da) 2011-10-31
KR20090114391A (ko) 2009-11-03
EP2117542B1 (en) 2011-08-17
EP2364704A1 (en) 2011-09-14
RS51956B (en) 2012-02-29
PT2117542E (pt) 2011-10-06
AR065277A1 (es) 2009-05-27
GB0702456D0 (en) 2007-03-21
JP2010518056A (ja) 2010-05-27
WO2008096111A1 (en) 2008-08-14
CL2008000379A1 (es) 2008-10-24
SI2117542T1 (sl) 2011-11-30
CA2675465A1 (en) 2008-08-14
AU2008212713A1 (en) 2008-08-14
BRPI0806964A2 (pt) 2014-04-08
IL199840A0 (en) 2010-04-15
MX2009007865A (es) 2009-07-31
US20100029732A1 (en) 2010-02-04
UY30906A1 (es) 2008-09-30
ECSP099567A (es) 2009-09-29

Similar Documents

Publication Publication Date Title
CY1111932T1 (el) Συνδυασμοι αγωνιστικης βητα-2-αδρενεργικης βενζοθειαζολονης
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
CY1117978T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
ATE459603T1 (de) Pyridinaminosulfonylsubstituierte benzamide als inhibitoren von cytochrom p450 3a4 (cyp3a4)
SI2182949T1 (sl) (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciklo(2.2.2)okt-3-il)benzofuran -2-karboksamid, nove oblike soli in postopki za njihovo uporabo
CL2008001868A1 (es) Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
MA29136B1 (fr) Agents de potentialisation de recepteurs du glutamate
NO20076498L (no) Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
HN2010002772A (es) Compuestos organicos nuevo titulo de la invencion: derivados de 2-(3-piridil)-indol sustituido y composicionesfarmaceuticas de los mismos. (bajo el escrito 2013-000513 de fecha 27 de febrero de 2013) solicitado por esta oficina de registro
CL2007003826A1 (es) Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion.
GT200500309A (es) Derivados de sulfonilbencilimidazol
UY30460A1 (es) Compuestos terapéuticos
CL2008003326A1 (es) Compuestos derivados de [(2r)-3-[2-(5-fluoro-4-pirimidinil)hidrazino]-3-oxopropil]hidroxiformamida, formas polimorficas 1, 2 y 3 de dichos compuestos; composicion farmaceutica; y su uso en el tratamiento de una enfermedad bacteriana del oido, sinusitis, infeccion del tracto respiratorio superior, entre otras.
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
AR072262A1 (es) COMBINACION -408, QUE COMPRENDE N-CICLOHEXIL-N3-[2-(3-FLUOROFENIL)ETIL]-N-(2-{[2-(4-HIDROXI-2-OXO-2,3-DIHIDRO-1,3-BENZOTIAZOL-7-IL)ETIL]AMINO}ETIL- beta-ALANINAMIDA.USO. METODO. CONJUNTO DE ELEMENTOS. COMPOSICION FARMACEUTICA. INTERMEDIARIO.
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
CY1111857T1 (el) Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης
NZ600266A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
SV2006002109A (es) Una composicion farmaceutica antimicobacteriana
AR063345A1 (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion